| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2001;103:1681.)
© 2001 American Heart Association, Inc.
Basic Science Reports |
From the Department of Cardiology and Institute of Experimental Clinical Research, Aarhus University Hospital, Denmark (J.F.B., E.F.); the Departments of General Practice (E.S.) and Forensic Toxicology (C.H.), Aarhus University, Denmark; the Department of Clinical Biochemistry, Aarhus University Hospital, Denmark (J.M.); the Department of Applied Chemistry, Université Victor Segalen Bordeaux II, France (N.S.); and the Department of Chemistry, University of Scranton, Pa (J.P.).
Correspondence to Jacob F. Bentzon, Dept of Cardiology, Research Unit, Aarhus University Hospital, Brendstrupgaardsvej, 8200 Aarhus N, Denmark. E-mail jab{at}studmed.au.dk
| Abstract |
|---|
|
|
|---|
Methods and ResultsEighty-four 7-week-old mice were randomized to receive water, red wine (diluted to 6% ethanol v/v), 6% ethanol v/v, or red wine powder in water. All mice were fed a normal chow diet. At 26 weeks of age, the mice were killed. HDL cholesterol was raised 12.0% (95% CI, 4.0% to 20.0%) and 9.2% (95% CI, 1.5% to 16.9%) by red wine and ethanol, respectively. At the end of study, all mice exhibited advanced atherosclerosis in the aortic bulb, whereas less mature atherosclerosis predominated in the brachiocephalic trunk. The amount of atherosclerosis in the aortic bulb and the brachiocephalic trunk were similar in all groups (P=0.92 and P=0.14, respectively). To evaluate whether ethanol or red wine polyphenols were protective by stabilizing atherosclerotic plaques rather than reducing their size, we measured the percentage of collagen-poor areas in left coronary sinus plaques as a morphological criterion of plaque stability. The percentage of collagen-poor areas did not differ between groups (P=0.71).
ConclusionsNeither ethanol nor red wine polyphenols reduced mature atherosclerosis or changed the content of collagen in plaques in apolipoprotein Edeficient mice.
Key Words: atherosclerosis alcohol antioxidants
| Introduction |
|---|
|
|
|---|
Coronary atherosclerotic plaque disruption with superimposed thrombosis is the main cause of myocardial infarction.2 It follows that the reduced incidence of myocardial infarction seen with drinkers could be caused by an inhibition of atherosclerosis, a stabilization of plaques, a reduction of plaque intrinsic thrombogenicity, or a reduction of the systemic propensity to thrombosis. Inhibition of atherosclerosis is a comprehensible pathway because ethanol consumption, as its hallmark, increases HDL cholesterol.3
A number of epidemiological studies have suggested a special protective effect of red wine,4 and this hypothesis has been supported by experimental research. Red wine polyphenols protect LDL from oxidation ex vivo5 and were recently shown to inhibit smooth muscle cell proliferation in vitro.6 Both properties could mediate an antiatherogenic effect.
Previous animal experiments have, with 1 exception,7 examined the effects of ethanol and red wine polyphenols only on fatty streaks (early atherosclerosis) because of either limitations of the animal model8 9 10 11 12 13 14 or a short study period.15 16 However, the development of fatty streaks may not reflect the pathogenesis of clinically relevant atherosclerosis.
Apolipoprotein Edeficient (apoE/) mice develop advanced, human-like atherosclerotic plaques in the aortic bulb, aortic arch, and the main aortic branches on a low-fat diet within 6 months of age.17 These plaques appear vulnerable by human morphological criteria but rarely rupture (Erling Falk, MD, PhD, unpublished data, 1999). We tested the hypothesis that treatment with ethanol or red wine polyphenols would reduce mature atherosclerosis or increase plaque stability by morphological criteria in apoE/ mice.
| Methods |
|---|
|
|
|---|
At 7 weeks of age, mice were randomized into 4 groups and given water (n=24), red wine (n=20), ethanol (n=20), or suspended red wine powder (n=20) as their only source of fluid. All mice were fed normal mouse chow (Altromin 1314). Red wine (Chateau de Paillas, Cahors, 1996, matured in steel vats) was diluted to an ethanol concentration of 6% v/v. Ethanol was prepared in a 6% v/v solution. Red wine powder (Clarét), was kindly provided by Poul Olsen, Pharmex Medical Aps, Hadsund, Denmark. Clarét is a spray-dried extract of unspecified Austrian red wine matured in steel vats. Fluid consumption was recorded, and all fluids were changed 3 times weekly. Body weights were recorded weekly. Comparability between red wine and red wine powder groups was sought by clamping the intake of condensed tannins, as measured by the colorimetric method of Ribereau-Gayon and Stonestreet18 with the correction for condensed tannins introduced by Glories.19 This was done by adjusting the concentration of the red wine powder suspension to correct for differences in fluid intake between the red wine and red wine powder groups.
After completion of the study, a more detailed analysis of
the polyphenol profiles of the red wine and red wine powder was done by
ETS Laboratories, St Helena, California. Briefly, red wine and red wine
powder (dissolved in methanol:water at 1:1 and sonicated for 5 minutes)
were centrifuged at 10 000 relative centrifugal force for 3
minutes. Wine phenolic compounds were then separated and quantitated by
high-performance liquid chromatography on the basis of comparison with
known standards. Total antioxidant status (TAS) of the consumed fluid
was evaluated using the kit from Randox Laboratories. Intakes of
polyphenols and antioxidant equivalents, as measured by these methods,
are listed in
Table 1
.
|
Ethanol in Blood
Ethanol concentrations in blood were measured at 9,
15, and 26 weeks of age in all mice in the red wine and ethanol groups,
as well as in control animals using headspace gas chromatography with
an internal standard. At 9 and 15 weeks, blood was obtained from the
retroorbital venous plexus. Results are expressed as percent
wt/wt.
End of Study
At 26 weeks of age, nonfasting mice were
anaesthetized (20 mg/kg midazolam IP, 40 mg/kg fluanisone IP, and 1.5
mg/kg fentanyl citrate IP) and exsanguinated by withdrawing blood from
the right ventricle into heparin-coated tubes. Thereafter, the mice
were flushed with St Thomas cardioplegic solution containing heparin,
perfusion-fixed at
100 mm Hg with 4% phosphate-buffered
formaldehyde (pH 7.2) via the left ventricle, and then immersed in the
fixative for 6 hours before storing in cold phosphate
buffer.
Pathoanatomical Examination
The heart, including the ascending aorta, was cut in
half; this was followed by paraffin embedding. The half containing the
aortic bulb was sectioned serially at 4-µm intervals. Once the aortic
sinuses appeared, every other section was collected on glass slides.
Five sections taken at 80-µm intervals, spanning 320 µm of the
aortic bulb from the commissures of the aortic leaflets and upward,
were stained with orcein and evaluated microscopically. The plaque area
was measured blindly by the same person (J.F.B.) using
computer-assisted image analysis (Olympus BX50 light microscope, Sony
DXC-151P color video camera, Imagraph Precision frame grabber, and
SigmaScan Pro from Jandel Scientific Software). The amount of
atherosclerosis in the aortic bulb was expressed as mean plaque size of
the 5 sections.
Sections (4 µm) of the brachiocephalic trunk were cut at 100-µm intervals from the aortic arch to the appearance of the subclaviancommon carotid bifurcation. Plaque area was measured as outlined above. Numbers are given as mean plaque size throughout the brachiocephalic trunk.
The percentage of collagen-poor areas was assessed in the left coronary sinus plaque. A section from the level of maximal plaque size was stained with Sirius Red, and collagen was detected by its birefringency using polarized light microscopy. Images were captured in Adobe Photoshop 5.0. Collagen-poor areas were defined as areas with a gray-scale level <50 units above background (Histogram function).
Plasma Analysis
Plasma total cholesterol, HDL cholesterol (HDL-C),
and triglycerides were measured enzymatically on a Cobas Fara analyzer
(Roche) using kits from Roche Diagnostics. TAS was determined
with the kit from Randox Laboratories. Each sample was assayed twice
with a coefficient of variation between duplicate samples of 7.7%. Lag
times of the Cu2+ oxidation of LDL+VLDL were
measured in 8 mice per group as previously
described.20
Statistical Methods
One-way ANOVA was used for comparisons of means. If
means were different by ANOVA, we used
t tests to determine the origin
of the difference. Triglycerides and plaque areas in the aortic bulb
and brachiocephalic trunk were log-transformed to normalize the
distribution. We used a t test
to calculate 95% confidence intervals (95% CI) of the effect (ratio
of geometric means) of red wine, ethanol, and red wine powder on aortic
bulb and brachiocephalic trunk atherosclerosis. SPSS 8.0 was used for
the calculations.
| Results |
|---|
|
|
|---|
Body Weight and Fluid Intake
Mice tolerated red wine, ethanol, and red wine powder
well. Fluid intake was 5.42±1.18, 4.88±0.63, 5.08±0.40, and
5.61±1.31 mL/day in the water, red wine, ethanol, and red wine powder
groups, respectively. Weight gain during the study was similar in all
groups, with final body weights of 33.1±3.2, 32.4±1.3, 31.8±2.6, and
32.7±2.3 g in the water, red wine, ethanol, and red wine powder
groups, respectively, (P=0.41
by ANOVA).
Ethanol in Blood
Sampling for determination of blood ethanol levels were
performed at 9 AM at 9
weeks of age and at 9 PM at
15 weeks of age
(Table 2
). At these sessions, 36% and 42%,
respectively, of the animals given alcohol had detectable blood ethanol
levels (>0.005%) that ranged up to 0.040%. At the end of study,
blood ethanol levels were much lower, probably due to lack of fluid
intake during the final transportation of the animals from the stable
to the laboratory.
|
Lipids
HDL-C rose 12.0% (95% CI, 4.0% to 20.0%) and 9.2%
(95% CI, 1.5% to 16.9%) after administration of red wine and
ethanol, respectively
(Table 3
). Total cholesterol was similar in all groups.
Surprisingly, mice given red wine had low triglycerides, whereas
neither ethanol nor red wine powder caused significant changes in
triglycerides.
|
Antioxidant Parameters
Blood obtained at death was analyzed for antioxidant
parameters, TAS, and lag times of LDL+VLDL oxidation
(Table 4
). As far as we know, plasma TAS values for
apoE/ mice have not been reported
previously. We found low plasma TAS compared with
humans21 and C57BL
mice.12 Paradoxically,
plasma TAS of the water-fed mice was higher than those of the other
groups. However, TAS correlated with triglyceride
(r=0.33,
P=0.003) and total cholesterol
levels (r=0.28,
P=0.012), and the higher TAS of
the water group seemed due, in part, to the effect of higher lipid
levels in this group. Ethanol and red wine increased the lag times of
LDL+VLDL oxidation, but red wine powder had no effect. Red wine did not
increase lag time compared with ethanol
(P=0.86 by
t test). Lag times correlated
inversely with triglyceride levels
(r=0.53,
P=0.002).
|
Atherosclerosis
At 26 weeks of age, all mice had mature atherosclerosis
in the aortic bulb resembling advanced human lesions
(Figure 1
). Mean plaque area was similar in all groups
(P=0.92 by ANOVA;
Figure 2
). The 95% CIs of the effect of red wine, ethanol,
and red wine powder were -24% to 65%, -23% to 66%, and -29%
to71%, respectively. To extend these observations, we quantitated
atherosclerosis in the brachiocephalic trunk by a novel method.
Atherosclerosis of the brachiocephalic trunk spanned from no lesion in
the distal part over a fatty streak to a mature plaque near the aortic
arch
(Figure 3
). Again, no differences in the amount of
atherosclerosis were detected between groups
(P=0.14 by ANOVA;
Figure 4
). The 95% CIs of the effect of red wine, ethanol,
and red wine powder on brachiocephalic trunk atherosclerosis were 2%
to 144%, 1% to 135%, and -29% to 96%, respectively. However,
these values were not significant by ANOVA.
|
|
|
|
The amount of atherosclerosis in the brachiocephalic trunk and the aortic bulb did not correlate (r=0.08, P=0.49). None of the potential risk factors (body weight, total cholesterol, HDL-C, triglycerides, TAS, and lag time) correlated with atherosclerosis in the aortic bulb or the brachiocephalic trunk (data not shown).
Plaque Composition
Atherosclerotic plaques in the aortic bulb consisted of
2 main components: a collagen-poor atheromatous (cholesterol crystals)
and a collagen-rich sclerotic component
(Figure 5
). The relative size of the collagen-poor component
is a morphological criterion of plaque vulnerability in
humans.22 Regarding plaques
in the 3 aortic sinuses of the bulb (see
Figure 1
), the largest plaque area was consistently found in
the left coronary sinus. To evaluate whether ethanol or red wine
polyphenols might influence the stability of atherosclerotic plaques,
we quantitated collagen content in the large left coronary sinus
plaque. The percentage of collagen-poor areas in left coronary sinus
plaques did not differ between groups (63.8±11.0%, 61.2±12.4%,
61.2±13.8%, and 58.9±16.7% in the water, red wine, ethanol, and red
wine powder groups, respectively;
P=0.71 by
ANOVA).
|
| Discussion |
|---|
|
|
|---|
Obviously, this lack of effect could be a true lack of antiatherogenic effect of ethanol and red wine polyphenols, but at least 2 other possibilities must be discussed. First, insufficient dosing would preclude a response. Second, a deviation of the biology of atherosclerosis in apoE/ mice from humans could obscure a true antiatherogenic effect.
Ethanol
The full cardioprotective effect of ethanol in
epidemiological studies is seen with intakes of
1 half-drink per
day.1 In the present study,
mice drank
5 mL of 6% ethanol per day. This translates into 6
drinks (of 12 g of ethanol) per day in a 70-kg man when
differences in metabolic capacities between mice and man are taken into
account.26 The data on blood
ethanol levels support this level of alcohol consumption. Also, the
magnitude of the HDL-C increase in the red wine and ethanol groups
corresponded to what is observed in human intervention studies of
3
to 4 drinks (of 12 g of ethanol) per
day.3 Thus, whether judged on
intake, blood concentration, or HDL-C response, the present model
constitutes an appropriate level of ethanol consumption.
In contrast to the HDL-C elevation caused by the expression of a human apolipoprotein A-I (apoA-I) transgene,23 ethanol-induced HDL-C increase did not protect against atherosclerosis in apoE/ mice. This may reflect a difference in quality between the 2 modes of HDL-C elevation and may apply to humans. Not all kinds of HDL-C elevation in humans seem to be protective.27 However, it is not clear whether the protective effect demonstrated in the human apoA-I transgene studies arose from increased HDL-C as such or from the introduction of the human genotype. Particularly intriguing, inactivation of the mouse apoA-I gene did not aggravate atherosclerosis in apoE/ mice in the single study reported.28 More needs to be learned about the physiology of mouse apoA-I before this point can be elucidated.
Red Wine Polyphenols
We did not measure plasma phenolic levels or urinary
phenolic excretion in the present study, but absorption of catechin and
quercetin has been demonstrated previously in the
apoE/ mouse model. Hayek et
al15 gave
apoE/ mice Cabernet Sauvignon red wine
containing a total polyphenol content of 50 µg of catechin
equivalents per day and detected catechin and quercetin in LDL at
concentrations of 3.65 nmol/mg LDL protein and 3.00 nmol/mg LDL
protein, respectively. This treatment lengthened lag time by 120
minutes and reduced fatty streak formation by 48% compared with 1.1%
ethanol-fed animals. We fed mice in the red wine group a higher dose
(containing 73 µg of monomeric catechin alone per day) but saw no
effect on mature atherosclerosis. In the present study, red wine did
not lengthen lag times compared with ethanol.
This discrepancy is not due to differences in polyphenol profiles between the used wines because Hayek et al15 found that 50 µg of catechin per day alone reduced fatty streak formation to almost the same extent (39%) and significantly lengthened lag time by 40 minutes.
Although we clamped the intake of condensed tannins between red wine and red wine powder groups, the detailed high-performance liquid chromatography assay revealed that polyphenol intakes were not comparable between these groups. The virtual absence of monomeric polyphenols in the red wine powder makes it difficult to dismiss the possibility that the lack of effect could be caused by a poor absorption of the contained oligomeric and polymeric polyphenols.
The fact that we did not demonstrate an ex vivo antioxidant effect of red wine polyphenols with the TAS assay or with the measurements of lag times may lead to questioning the appropriateness of the apoE/ mouse as a model to study antioxidant effects on atherosclerosis. However, a number of observations points toward the apoE/ mouse as a suitable model for exactly that. First, LDL oxidation occurs in the atherosclerotic plaques of these mice.29 Second, although unmodified VLDL remnant particles might be atherogenic in humans through apoE-mediated macrophage internalization, the lack of apoE in apoE/ mice abolishes this pathway, thus exaggerating the role of oxidation and other kinds of lipoprotein modification. Convincingly, a disruption of the gene for scavenger class A receptors that internalize oxidized LDL in macrophages attenuates advanced atherosclerosis in apoE/ mice by 58%.24 Third, the antioxidants vitamin E30 and N,N'-diphenyl-1,4-phenylenediamine31 inhibit advanced atherosclerosis in this model, although it remains uncertain if the effect of these drugs can be attributed to their mere antioxidant activity because another antioxidant, probucol, accelerates atherosclerosis in apoE/ mice.28
Fatty Streaks Versus Mature
Atherosclerosis
Our finding that neither red wine nor ethanol protect
against mature atherosclerosis in apoE/
mice is in contrast with a number of experiments in animal models of
fatty streak
formation.7 8 9 10 11 12 13 14 15 16
Although not necessarily in conflict with these studies, it challenges
the implications that have been drawn from them. Red wine polyphenols
and ethanol may inhibit fatty streak formation even in humans, but if
this effect is lost with the progression of atherosclerosis, it is of
limited interest clinically. In apoE/
mice, numerous studies have identified treatments capable of inhibiting
fatty streak formation,32
but the clinical relevance of these are hampered by recent results that
suggest qualitative differences in the pathogenesis of early versus
late stages of atherosclerosis in apoE/
mice. Antibodies against the macrophage-colonystimulating factor
receptor
c-fms,25
transplantation of apoE-transduced bone
marrow,33 and fibrinogen
deficiency34 all reduce
fatty streaks in apoE/ mice but do not
reduce atherosclerosis at the late stage. Our study adds red wine
polyphenols to this growing list. The discrepancies are not caused by a
general insensitivity of the advanced atherosclerotic process to
intervention, because the advanced stage can be attenuated by a number
of substances, including high-dose vitamin
E30 and
N,N'-diphenyl-1,4-phenylenediamine,31
reversed by liver-directed apoE gene
transfer,35 and aggravated
by probucol28 or by feeding
the mice a Western-type
diet.17 Recently, a genetic
disruption of CD154 was shown to reduce advanced atherosclerosis in
apoE/ mice without influencing fatty
streak formation.36 The
possibility of important pathogenetic differences between fatty streaks
and mature atherosclerosis has become a topic of increasing
awareness.37
| Conclusions |
|---|
|
|
|---|
Study Limitations
Better understanding of the physiology of mouse apoA-I
is necessary to fully understand the relevance of the mouse as a model
to examine the effects of ethanol-induced HDL-C elevation. Also, the
surprising antioxidant parameter findings and lowering of triglycerides
with intake of red wine raise the question of the generalizability from
this genetically defined animal model to human
atherosclerosis. >
| Acknowledgments |
|---|
Received August 9, 2000; revision received September 25, 2000; accepted September 26, 2000.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
M. Sarr, M. Chataigneau, S. Martins, C. Schott, J. El Bedoui, M.-H. Oak, B. Muller, T. Chataigneau, and V. B. Schini-Kerth Red wine polyphenols prevent angiotensin II-induced hypertension and endothelial dysfunction in rats: Role of NADPH oxidase Cardiovasc Res, September 1, 2006; 71(4): 794 - 802. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. L. Sorensen, J. Madsen, K. Kejling, I. Tornoe, O. Nielsen, P. Townsend, F. Poulain, C. H. Nielsen, K. B. M. Reid, S. Hawgood, et al. Surfactant protein D is proatherogenic in mice Am J Physiol Heart Circ Physiol, June 1, 2006; 290(6): H2286 - H2294. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. E. Szmitko and S. Verma Antiatherogenic potential of red wine: clinician update Am J Physiol Heart Circ Physiol, May 1, 2005; 288(5): H2023 - H2030. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. S. Meir and E. Leitersdorf Atherosclerosis in the Apolipoprotein E-Deficient Mouse: A Decade of Progress Arterioscler. Thromb. Vasc. Biol., June 1, 2004; 24(6): 1006 - 1014. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Waddington, I. B Puddey, and K. D Croft Red wine polyphenolic compounds inhibit atherosclerosis in apolipoprotein E-deficient mice independently of effects on lipid peroxidation Am. J. Clinical Nutrition, January 1, 2004; 79(1): 54 - 61. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Stocker and R. A O'Halloran Dealcoholized red wine decreases atherosclerosis in apolipoprotein E gene-deficient mice independently of inhibition of lipid peroxidation in the artery wall Am. J. Clinical Nutrition, January 1, 2004; 79(1): 123 - 130. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Bro, J. F. Bentzon, E. Falk, C. B. Andersen, K. Olgaard, and L. B. Nielsen Chronic Renal Failure Accelerates Atherogenesis in Apolipoprotein E-Deficient Mice J. Am. Soc. Nephrol., October 1, 2003; 14(10): 2466 - 2474. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Teupser, A. D. Persky, and J. L. Breslow Induction of Atherosclerosis by Low-Fat, Semisynthetic Diets in LDL Receptor-Deficient C57BL/6J and FVB/NJ Mice: Comparison of Lesions of the Aortic Root, Brachiocephalic Artery, and Whole Aorta (En Face Measurement) Arterioscler. Thromb. Vasc. Biol., October 1, 2003; 23(10): 1907 - 1913. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Vogel Vintners and vasodilators: are French red wines more cardioprotective? J. Am. Coll. Cardiol., February 5, 2003; 41(3): 479 - 481. [Full Text] [PDF] |
||||
![]() |
J. F. Bentzon, G. Pasterkamp, and E. Falk Expansive Remodeling Is a Response of the Plaque-Related Vessel Wall in Aortic Roots of ApoE-Deficient Mice: An Experiment of Nature Arterioscler. Thromb. Vasc. Biol., February 1, 2003; 23(2): 257 - 262. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. J. Goldberg To Drink or Not to Drink? N. Engl. J. Med., January 9, 2003; 348(2): 163 - 164. [Full Text] [PDF] |
||||
![]() |
S. Peele, I. J. Goldberg, L. Mosca, M. R. Piano, and E. A. Fisher American Heart Association Advisory, "Wine and Your Heart," Is Not Science-Based Response Circulation, September 25, 2001; 104 (13): e73 - e73. [Full Text] [PDF] |
||||
![]() |
Y. Nakata and N. Maeda Vulnerable Atherosclerotic Plaque Morphology in Apolipoprotein E-Deficient Mice Unable to Make Ascorbic Acid Circulation, March 26, 2002; 105(12): 1485 - 1490. [Abstract] [Full Text] [PDF] |
||||